Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 109

Sort by

Sort Order Select

Journal Articles

Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88

Blood (2021) 137 (18): 2495–2508.

https://doi.org/10.1182/blood.2020008414

Published: 2021

Includes: Supplemental data

Journal Articles

Hyperphosphatemia Contributes to Inflammation and Iron Dysregulation in Models of Normal and Impaired Renal Function

Brian Czaya, BS, MSc, Beatrice Richter, PhD, Christopher Yanucil, Bsc, Isaac Campos, Bsc, Kylie Heitman, Bsc, Christian Faul, PhD

Blood (2019) 134 (Supplement_1): 2238.

https://doi.org/10.1182/blood-2019-122144

Published: 2019

Journal Articles

Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies

Jacqueline S Garcia, MD, Helen I. Gandler, Geoffrey Fell, MS, Ashlee J. Fiore, Donna S Neuberg, ScD, Adrienne Anderson, Kelsey O'Day, Marlise Luskin, MDMS, Martha Wadleigh, MD, Eric S. Winer, MD, Ilene Galinsky, Daniel J. DeAngelo, MD, David A. Frank, MD PhD, Richard M. Stone, MD

Blood (2019) 134 (Supplement_1): 2549.

https://doi.org/10.1182/blood-2019-126224

Published: 2019

Journal Articles

Myeloma Heterogeneity within Its Complex Immune Ecosystem

Jana Jakubikova, PhD, Danka Cholujova, PhD, Gabor Beke, PhD, Zachary R Hunter, PhD, Teru Hideshima, MD PhD, Merav Leiba, MD, Krzysztof Jamroziak, MD PhD, Paul G. Richardson, MD, Eftathios Kastritis, David M. Dorfman, MD PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 4354.

https://doi.org/10.1182/blood-2019-132193

Published: 2019

Journal Articles

Targeted FGFR Inhibition Results in Hematologic and Cytogenetic Remission in a Myeloid Neoplasm Driven By a Novel PCM1-FGFR1 Fusion: Data from an Expanded Access Program

Monica Kasbekar, Valentina Nardi, MD, Paola Dal Cin, Andrew M. Brunner, MD, Yi-Bin Chen, Christine Connolly, Amir T. Fathi, MD, Julia Foster, ANP, Molly Macrae, Steven L McAfee, MD, Kristin McGregor, Rupa Narayan, Aura Y. Ramos, Tina T. Som, RN, Megan Vartanian, RN, Robb S Friedman, MD, Karim Benhadji, MD MSC, Gabriela S. Hobbs, MD

Blood (2019) 134 (Supplement_1): 5371.

https://doi.org/10.1182/blood-2019-124100

Published: 2019

Journal Articles

Genome-Wide CRISPR Screening Identifies MAPK and Mtorc Pathways As Regulators of Sorafenib Resistance in Acute Myeloid Leukemia

Alisa Damnernsawad, PhD, Tamilla Nechiporuk, PhD, Daniel Bottomly, MS, Stephen E Kurtz, PhD, Christopher A. Eide, Shannon K. McWeeney, PhD, Jeffrey W. Tyner

Blood (2019) 134 (Supplement_1): 2557.

https://doi.org/10.1182/blood-2019-128877

Published: 2019

Journal Articles

High-Dimensional Heterogeneity of Waldenström Macroglobulinemia within Its Immune Tumor Microenvironment

Jana Jakubikova, PhD, Danka Cholujova, PhD, Gabor Beke, PhD, Zachary R Hunter, PhD, Teru Hideshima, MD PhD, Ludmila Flores, Merav Leiba, MD, Paul G. Richardson, MD, Eftathios Kastritis, David M. Dorfman, MD PhD, Steven P Treon, MD PhD FRCP, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 3975.

https://doi.org/10.1182/blood-2019-130011

Published: 2019

Journal Articles

Overcoming the Supportive Stroma-Induced Proliferation in Waldenstrom's Macroglobulinemia By Selective Inhibition of the FGF/FGF-Receptor Axis

Cinzia Federico, PhD, Antonio Sacco, RN, Katia Todoerti, PhD, Arianna Giacomini, PhD, Gaia C Ghedini, PhD, Gaetana Lanzi, PhD, Marina Motta, MD, Antonella Anastasia, MD, Vanessa Favasuli, Roberto Ronca, PhD, Silvia Giliani, PhD, Nicole Bozza, PhD, Riccardo Castelli, PhD, Giuseppe Rossi, Antonino Neri, MD, Marco Mor, PhD, Marco Presta, PhD, Aldo M. Roccaro, MD PhD

Blood (2019) 134 (Supplement_1): 1822.

https://doi.org/10.1182/blood-2019-126554

Published: 2019

Journal Articles

Erythropoietin Is Associated with a Decline in the iFGF23/cFGF23 Ratio in Patients with Various Hereditary Hemolytic Anemias

Annelies J. Van Vuren, MD, Michele F. Eisenga, MD PhD, Stephanie van Straaten, MD PhD, Andreas Glenthøj, MD PhD, Carlo A.J.M. Gaillard, MD PhD, Stephan J.L. Bakker, MD PhD, Martin H. de Borst, MD PhD, Richard van Wijk, PhD, Eduard J. van Beers, MD PhD

Blood (2019) 134 (Supplement_1): 4793.

https://doi.org/10.1182/blood-2019-124074

Published: 2019

Journal Articles

Fibroblast Growth Factor-1 Inhibition Enhances FAS-Induced Apoptosis in Mantle Cell Lymphoma Cells By Accelerated BIRC2/3 Degradation

Lalit Sehgal, PhD, Neeraj Jain, Khashab Tamer, MD, Natalie Willingham, Felipe Samaniego, MD

Blood (2018) 132 (Supplement 1): 2859.

https://doi.org/10.1182/blood-2018-99-116691

Published: 2018

Journal Articles

Preclinical Evaluation of MAX-40279, a FLT3/FGFR Dual Kinase Inhibitor for Treatment of Acute Myeloid Leukemia

Yuguang Wang, PhD, Hanying Bao, MD PhD, Nong Zhang, PhD, Feilan Wang, PhD, Yunsong He, MD, Tianzhi Wu, PhD

Blood (2018) 132 (Supplement 1): 3997.

https://doi.org/10.1182/blood-2018-99-110414

Published: 2018

Journal Articles

Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 ( FGFR1 )

Srdan Verstovsek, MD PhD, Alessandro M. Vannucchi, MD, Alessandro Rambaldi, MD PhD, Jason R. Gotlib, MDMS, Adam J. Mead, MD PhD, Andreas Hochhaus, MD, Jean-Jacques Kiladjian, MD PhD, Juan Carlos Hernandez Boluda, MD PhD, Ekaterine Asatiani, MD, Christine Lihou, BS, Huiling Zhen, MD PhD, Andreas Reiter, MD

Blood (2018) 132 (Supplement 1): 690.

https://doi.org/10.1182/blood-2018-99-110388

Published: 2018

Journal Articles

Enhanced Expression of FGF Signaling in Primary Central Nervous System Lymphoma

Alanna Maguire, PhD MSc, Talal Hilal, MBBChir, Xianfeng Chen, BSc, Allison C. Rosenthal, DO, Lisa M. Rimsza, MD

Blood (2018) 132 (Supplement 1): 2847.

https://doi.org/10.1182/blood-2018-99-116416

Published: 2018

Journal Articles

Preclinical Rationale for the Use of Regorafenib in Myeloid Malignancies

Gabriela S. Hobbs, MD, Andrew M. Brunner, MD, Timothy A. Graubert, MD, Cyril H Benes, Gabriel Daniel Duda, DMD, PhD, Yi-Bin Chen, MD

Blood (2017) 130 (Supplement 1): 2643.

https://doi.org/10.1182/blood.V130.Suppl_1.2643.2643

Published: 2017

Journal Articles

High Expression of FGF2/SDC1 Signaling Contributes to Poor Clinical Outcome in Hodgkin Lymphoma Patients and SDC1 siRNA Suppresses Proliferation, Migration, and Invasion in Hodgkin Lymphoma Cells

Blood (2017) 130 (Supplement 1): 1483.

https://doi.org/10.1182/blood.V130.Suppl_1.1483.1483

Published: 2017

Journal Articles

Marrow Stromal Cells Secrete FGF2 in Exosomes, Providing Paracrine Protection for Leukemia Cells from Kinase Inhibitors

Elie Traer, MD PhD, Brian J. Druker, MD, Jakki Martinez, Nathalie Javidi-Sharifi, Isabel English, BA, Anupriya Agarwal, PhD, Jennifer Dunlap, MD

Blood (2017) 130 (Supplement 1): 306.

https://doi.org/10.1182/blood.V130.Suppl_1.306.306

Published: 2017

Journal Articles

Targeting Lymphoplasmacytic Lymphoma through a Novel Anti-FGF-Based Therapeutical Strategy

Antonio Sacco, Loredana Affò, Gaia C Ghedini, Gaetana Lanzi, Arianna Giacomini, Marina Motta, Antonella Anastasia, Claudia Ghidini, Marco Chiarini, Silvia Giliani, Roberto Ronca, Luisa Imberti, MD, Alessandro Montanelli, MD, Nicole Bozza, Riccardo Castelli, Giuseppe Rossi, MD, Marco Mor, Marco Presta, Aldo M. Roccaro

Blood (2017) 130 (Supplement 1): 2818.

https://doi.org/10.1182/blood.V130.Suppl_1.2818.2818

Published: 2017

Journal Articles

CD200 Is a Potent New Growth Factor in Multiple Myeloma through IGF-1R Interaction

Angélique Bruyer, MSc, Nicolas Robert, Stéphanie Boireau, Christophe Hirtz, Laurent Tiers, Laure Vincent, Guillaume Cartron, Dirk Hose, MD, Anja Seckinger, Bernard Klein, PhD, Jerome Moreaux, PhD

Blood (2017) 130 (Supplement 1): 3045.

https://doi.org/10.1182/blood.V130.Suppl_1.3045.3045

Published: 2017

Journal Articles

A Novel JAK2 Mutation Confers Cytokine-Independence in the Absence of a Type I Dimeric Cytokine Receptor

Ami B. Patel, MD, Anca Franzini, PhD, Emilie Leroy, PhD, Dongqing Yan, Anna M. Eiring, PhD, Stefan N. Constantinescu, MD PhD, Thomas O'Hare, PhD, Michael W. Deininger, MD PhD

Blood (2017) 130 (Supplement 1): 4212.

https://doi.org/10.1182/blood.V130.Suppl_1.4212.4212

Published: 2017

Journal Articles

FGF2 from Bone Marrow Stroma Protects Acute Myeloid Leukemia Cells from the FLT3 Inhibitor Quizartinib and Facilitates Acquisition of Resistance Mutations

Elie Traer, MD, Nathalie Javidi-Sharifi, Jacqueline Martinez, MS, Isabel English, Jennifer Dunlap, MD, Anupriya Agarwal, Tibor J. Kovacsovics, MD, Jeffrey W. Tyner, Melissa Wong, PhD, Brian J. Druker, MD

Blood (2016) 128 (22): 1080.

https://doi.org/10.1182/blood.V128.22.1080.1080

Published: 2016

NARROW

Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88

Hyperphosphatemia Contributes to Inflammation and Iron Dysregulation in Models of Normal and Impaired Renal Function

Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies

Myeloma Heterogeneity within Its Complex Immune Ecosystem

Targeted FGFR Inhibition Results in Hematologic and Cytogenetic Remission in a Myeloid Neoplasm Driven By a Novel PCM1-FGFR1 Fusion: Data from an Expanded Access Program

Genome-Wide CRISPR Screening Identifies MAPK and Mtorc Pathways As Regulators of Sorafenib Resistance in Acute Myeloid Leukemia

High-Dimensional Heterogeneity of Waldenström Macroglobulinemia within Its Immune Tumor Microenvironment

Overcoming the Supportive Stroma-Induced Proliferation in Waldenstrom's Macroglobulinemia By Selective Inhibition of the FGF/FGF-Receptor Axis

Erythropoietin Is Associated with a Decline in the iFGF23/cFGF23 Ratio in Patients with Various Hereditary Hemolytic Anemias

Fibroblast Growth Factor-1 Inhibition Enhances FAS-Induced Apoptosis in Mantle Cell Lymphoma Cells By Accelerated BIRC2/3 Degradation

Preclinical Evaluation of MAX-40279, a FLT3/FGFR Dual Kinase Inhibitor for Treatment of Acute Myeloid Leukemia

Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 ( FGFR1 )

Enhanced Expression of FGF Signaling in Primary Central Nervous System Lymphoma

Preclinical Rationale for the Use of Regorafenib in Myeloid Malignancies

High Expression of FGF2/SDC1 Signaling Contributes to Poor Clinical Outcome in Hodgkin Lymphoma Patients and SDC1 siRNA Suppresses Proliferation, Migration, and Invasion in Hodgkin Lymphoma Cells

Marrow Stromal Cells Secrete FGF2 in Exosomes, Providing Paracrine Protection for Leukemia Cells from Kinase Inhibitors

Targeting Lymphoplasmacytic Lymphoma through a Novel Anti-FGF-Based Therapeutical Strategy

CD200 Is a Potent New Growth Factor in Multiple Myeloma through IGF-1R Interaction

A Novel JAK2 Mutation Confers Cytokine-Independence in the Absence of a Type I Dimeric Cytokine Receptor

FGF2 from Bone Marrow Stroma Protects Acute Myeloid Leukemia Cells from the FLT3 Inhibitor Quizartinib and Facilitates Acquisition of Resistance Mutations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only